SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

KENDU.X is trending as the community rallies around its real-world applications, including Kendu Energy drinks, and a forthcoming game. The conversation highlights the community's strong conviction and continuous building, emphasizing that KENDU goes beyond just a memecoin. Discussions also focus on holder growth and the project's unique status as a permissionless brand.

Linea is the Layer 2 built from first principles to strengthen Ethereum and the entire ETH economy. Every aspect of its design—from its productive ETH burn mechanics, and capital efficient native yield, to its underlying Ethereum-equivalent zk tech—amplifies the value and utility of Ethereum Mainnet. All of this is backed by the largest ecosystem fund in the space, managed by the most trusted Ethereum builders. With institutional-grade infrastructure, and deep integration across DeFi, Linea is the best chain for ETH capital, where every transaction and every block strengthens Ethereum. Linea is where Ethereum wins.

Linea

Linea is trending as the community discusses its potential integration with SWIFT, a global banking network, and what this could mean for the future of cross-border payments. Some believe this positions Linea favorably against competitors like XRP, while others are exploring price predictions and related coins. The discussion highlights the possible implications of blockchain technology in traditional finance.

Mamo turns what used to be complex into easy, human-first routines.  It works quietly in the background, finding smart opportunities for your money while you focus on what matters in your life. Think of Mamo as your knowledgeable friend who understands how to help your money grow and explain everything in plain language.  Behind the scenes, Mamo applies proven strategies and real-time data to optimize your portfolio, reinvest earnings when conditions are right, and adapt to market shifts — all with your approval and full transparency.  No noise. No confusion. Just calm, steady growth.

Mamo

MAMO.X is trending as users discuss its potential, focusing on its AI capabilities and the anticipation of the Base App launch, which is expected to expose the crypto to millions of new users. Community members highlight the coin's potential for significant growth and its connection to major players like Coinbase, while also pointing out its volatility. Speculation around price targets and future listings is fueling the conversation.

BTQ Technologies Corp. engages in the business of post-quantum encryption. It focuses on applications to the blockchain industry. Its products include PQScale, Keelug, Kenting, Preon, QPoW, and QByte. The company was founded by Nicolas Roussy Newton on March 26, 2021 and is headquartered in Vancouver, Canada.

BTQ Technologies Corp

BTQ Technologies is trending due to discussions around its Nasdaq uplisting and potential for quantum-secure applications, though the initial market reaction has been mixed. Community members are weighing the potential benefits of increased visibility against concerns of possible dilution and comparing it to similar situations with other stocks. The stock's future direction is tied to its ability to secure revenue-generating partnerships and navigate the evolving landscape of quantum cybersecurity.

FFFFFFFFFFFFFUUUUUUUUUUUUUUUU

$RAGEGUY.X is gaining attention as traders discuss its potential for a "V-shape recovery" and highlight opportunities to load up, particularly on platforms like Phantom Wallet. Community members are actively sharing DEX screener links and pointing to possible catalysts for significant upward movement. Some users are drawing comparisons to other tokens and joke coins.

Bed Bath & Beyond, Inc. engages in the provision of an e-commerce platform. It offers furniture and home furnishing products and services. The company was founded on May 5, 1997 and is headquartered in Murray, UT.

Bed Bath & Beyond Inc.

Bed Bath & Beyond Inc

BBBY is trending due to community discussions around a potential warrant dividend and its connection to GME, sparking speculation about a possible squeeze.  Additionally, Marcus Lemonis's leadership and the company's blockchain initiatives, particularly TZero, are being closely watched. Some traders are drawing parallels to meme stock rallies, while others express skepticism about the long-term viability of the company's turnaround.

Marsh & McLennan Cos., Inc. is a professional services firm, which engages in offering clients advice and solutions in risk, strategy, and people. It operates through the Risk and Insurance Services, and Consulting segments. The Risk and Insurance Services segment is involved in risk management activities, as well as insurance and reinsurance broking and services. The Consulting segment offers health, wealth, and career solutions and products, and specialized management, strategic, economic, and brand consulting services. The company was founded by Henry W. Marsh and Donald R. McLennan in 1871 and is headquartered in New York, NY.

Marsh & McLennan Cos., Inc.

MMC is trending as investors assess whether it's a good time to buy amid discussions of the company trading at a discount and strong earnings growth potential. While some view it as an opportunity to "buy the dip", others are wary of rising costs and debt impacting margins. Community members are actively discussing the company's revenue boost and potential to reach previous highs.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending as investors discuss potential R2 production timelines and the implications of its rollout. Community members are actively debating vehicle quality and reliability, especially concerning software updates and repair costs, influencing sentiment. Recent option activity suggests a mixed outlook, while some analysts express caution regarding the company's investment strategy and cash flow.

QXO, Inc. is a publicly traded distributor of roofing, waterproofing and complementary building products in the United States. It plans to become tech-enabled in the building products distribution industry and generate outsized value for shareholders. The company was founded on October 3, 2002, and is headquartered in Greenwich, CT.

QXO Inc.

QXO is trending as investors discuss the potential for significant revenue growth through acquisitions and AI-driven operational improvements within the fragmented building products industry. Community members are debating the company's current valuation and future prospects, with some expressing frustration over recent stock performance while others remain confident in the management's long-term strategy. Discussions also include potential acquisition targets and the impact of macroeconomic factors like interest rate cuts on the housing market.

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizer is trending as the community debates its strategic direction, particularly following news of potential acquisitions and renewed focus on the obesity market. Community members are actively discussing the company's pipeline, potential value, and comparing it to competitors within the broader pharmaceutical landscape. Some traders are monitoring for short-term opportunities, while others are weighing long-term prospects amid evolving market dynamics and upcoming catalysts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?

Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.

Shares of Immuneering Corp. rose 42% in after-hours trading on Wednesday after the company’s Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel showed an 86% overall survival rate in patients with first-line pancreatic cancer at nine months, compared with a 47% benchmark for standard of care.The stock closed Wednesday’s regular session up 7.5% at $9.23.Immuneering said it plans to seek regulatory feedback on its pivotal trial plans in the fourth quarter and, subject to that feedback, aims to launch a Phase 3 trial of atebimetinib plus mGnP by the end of 2025, with patient dosing to begin by mid-2026.&nbsp;The company also expects to initiate additional atebimetinib clinical trial combination arms in 2026, including in non-small cell lung cancer.Progression-free survival at nine months was 53%, compared to a 29% benchmark for standard of care. At six months, overall survival was 94%, and progression-free survival was 70%, both&nbsp;rates exceeding&nbsp;historical benchmarks. Median overall survival has not yet been reached.The treatment was generally well-tolerated. The serious side effects,&nbsp;observed in more than 1 in 10 people, included low white blood cell counts, which can increase the risk of infection, and anemia, characterized by low red blood cell levels. No new safety concerns were identified.CEO Ben Zeskind said the nine-month overall survival data widened the gap against&nbsp;the standard of care, describing the results as “extraordinary.” Chief Scientific Officer Brett Hall said atebimetinib, designed as a Deep Cyclic Inhibitor, represents a “fundamental shift in targeted therapy.”&nbsp;Vincent Chung, principal investigator of the trial at City of Hope, said the results mark “an important step” toward urgently needed new treatment options for pancreatic cancer, adding that the company is also planning a confirmatory study.&nbsp;Separately, Immuneering announced a proposed underwritten public offering of its Class A common stock, or in lieu of stock, pre-funded warrants. The company also stated that Sanofi agreed to purchase $25 million of shares in a concurrent private placement at the public offering price, with both transactions expected to close simultaneously.&nbsp;Immuneering plans to use the proceeds to advance the development of its drug candidates and for general corporate purposes.On Stocktwits, retail sentiment for Immuneering was ‘extremely bullish’ amid a 3,540% surge in 24-hour message volume, placing it among the top 10 trending equities on the platform.&nbsp;One user said the offering “didn’t completely kill the momentum,” adding that it gave them hope for the next trading day.&nbsp;<stembedurl>https://stocktwits.com/Mushichka/message/629894873</stembedurl>Another user said they were in “for the long haul, which now extends into mid-2026,” and added that the stock offering would likely be shrugged off within a day before analysts begin calculating Immuneering’s valuation based on potential sales of what they described as the gold standard for treating pancreatic cancer.<stembedurl>https://stocktwits.com/OptimistJP/message/629894127</stembedurl><a href="https://stocktwits.com/symbol/IMRX">Immuneering’s stock</a> has surged 320% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Immuneering’s stock (IMRX) has surged 320% so far in 2025. (Photo credit: Getty Images)

Why Immuneering Stock Soared Over 40% After-Hours Today

Updated trial data showed its drug atebimetinib nearly doubled survival benchmarks in first-line pancreatic cancer, with the company planning a pivotal Phase 3 study by late 2025.

Equity

SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU

Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.

FDA Extends Review Period of Sanofi's Multiple Sclerosis Drug Filing

The FDA extends SNY's tolebrutinib NDA review by three months, with decision now expected on Dec. 28, 2025.

Rigel Gains 77% in 3 Months: Is This an Indication to Buy the Stock?

RIGL shares surge 77% in three months as Tavalisse drives record sales along with other products while boosting the company's 2025 outlook.

REGN Loses 21.1% Year to Date: Buy, Sell or Hold the Sock?

Regeneron shares slump as Eylea struggles, but Dupixent gains and a strengthening oncology pipeline offer growth potential.

SNY's Gene Therapy Candidate for Eye Disease Gets FDA Fast Track Tag

Sanofi's gene therapy SAR402663 for wet AMD earns FDA fast track status, aiming to speed up development and reduce treatment burden.

Can Tavalisse Drive Rigel's Growth Through the Rest of 2025?

RIGL's top line keeps growing on strong sales momentum for lead product, Tavalisse, while other products support growth.

NKTR Shares Surge 38.2% in a Week: Here's What You Should Know

Nektar shares surge 38.2% on investor optimism on rezpeg's potential in atopic dermatitis after upbeat mid-stage study results.

SNY Down Despite Eczema Candidate Meeting Goal in Phase III Study

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in patients.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

SNY
Sanofi-Aventis

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SNY News

SNY Sanofi-Aventis